HomeCYBN • NYSEAMERICAN
add
Cybin Inc
$7.52
Pre-market:(0.13%)+0.010
$7.53
Sarado: Hul 17, 4:07:51 AM GMT-4 · USD · NYSEAMERICAN · Disclaimer
Nakaraang pagsara
$7.41
Sakop ng araw
$7.33 - $7.55
Sakop ng taon
$4.81 - $13.88
Average na Volume
369.01K
P/E ratio
-
Dividend yield
-
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (CAD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 33.24M | 31.95% |
Net na kita | -30.58M | -43.25% |
Net profit margin | — | — |
Kita sa bawat share | -1.46 | -92.14% |
EBITDA | -33.19M | -32.03% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CAD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 135.02M | -35.39% |
Kabuuang asset | 258.62M | -14.37% |
Kabuuang sagutin | 21.42M | 112.14% |
Kabuuang equity | 237.20M | — |
Natitirang share | 23.03M | — |
Presyo para makapag-book | 0.67 | — |
Return on assets | -32.45% | — |
Return on capital | -34.81% | — |
Cash Flow
Net change in cash
| (CAD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -30.58M | -43.25% |
Cash mula sa mga operasyon | -21.11M | -1.96% |
Cash mula sa pag-invest | -1.08M | -404.19% |
Cash mula sa financing | 20.98M | -89.01% |
Net change in cash | -1.27M | -100.75% |
Malayang cash flow | -11.14M | 12.30% |
Tungkol
Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, CYB002, CYB003, CYB004, CYB005, and CYB006. Another drug that the company has developed is CYB210010.
As of January 2025, CYB003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics. Wikipedia
Itinatag
2019
Headquarters
Website
Mga Empleyado
50
